{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
glutathione disulfide
to a specific field?
Status:
Investigational
Source:
NCT01794663: Phase 2 Interventional Completed Delayed Graft Function
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01446159: Phase 2 Interventional Completed Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02745119: Phase 3 Interventional Terminated Geographic Atrophy
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04363801: Phase 2 Interventional Active, not recruiting Gastric Cancer
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01897480: Phase 2 Interventional Active, not recruiting Carcinoma, Non-Small-Cell Lung
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01604408: Phase 2 Interventional Completed Muscle Weakness
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01691898: Phase 1/Phase 2 Interventional Completed Follicular Lymphoma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03341936: Phase 2 Interventional Active, not recruiting Squamous Cell Carcinoma of the Head and Neck
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02095626: Phase 2 Interventional Completed PGD Primary Graft Dysfunction
(2013)
Source URL:
Class:
PROTEIN
Apeptico is developing solnatide (AP301), a dry powder inhalation and an inhaled aerosol formulation of a synthetic peptide for the treatment of acute lung injury, acute respiratory distress syndrome and pulmonary oedema caused by lung infection or high altitude. The AP301 peptide mimics the lectin-like domain of TNF-α. The synthetic peptide AP301 is composed of 17 amino acids and contains an intramolecular disulfide bond between the N-terminal and the C-terminal cysteine. AP301 interacts with the endothelial sodium channel (ENaC) and activates pulmonary liquid clearance both in vitro and in animal studies. The specific interaction of AP301 with both endogenously and heterologously expressed ENaC requires precedent binding to glycosylated extracellular loop(s). Solnatide has been granted Orphan Drug Designation for “Treatment of Primary Graft Dysfunction following Lung Transplantation” and for “Treatment of Pseudohypoaldosteronism Type 1B” by the Food and Drug Administration.
Status:
Investigational
Source:
NCT03961815: Phase 3 Interventional Terminated Crohn's Disease
(2020)
Source URL:
Class:
PROTEIN
